* Surmodics Inc SRDX.OQ SRDX.O is expected to show a
rise in
quarterly revenue when it reports results on January 31
(estimated) for the period ending December 31 2024
* The Eden Prairie Minnesota-based company is expected to
report
a 9.2% increase in revenue to $33.367 million from $30.55
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Surmodics Inc is for a
loss
of 12 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Surmodics
Inc is
$43.00, above its last closing price of $35.79.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2024 -0.30 -0.29 -0.13 Beat 55.8
Jun. 30 2024 -0.33 -0.33 -0.27 Beat 18.2
Mar. 31 2024 -0.32 -0.32 0.07 Beat 121.9
Dec. 31 2023 -0.32 -0.30 0.00 Beat 100
Sep. 0.18 0.19 0.53 Beat 186.5
30 2023
Jun. 30 2023 -0.22 0.05 0.52 Beat 893.7
Mar. 31 2023 -0.49 -0.51 -0.40 Beat 21.3
Dec. 31 2022 -0.65 -0.66 -0.50 Beat 23.8
This summary was machine generated January 29 at 13:34 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)